DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-10 are pending.
Claims 6-10 are withdrawn from consideration as directed to a non-elected invention.
Claims 1-5 are presented for examination and rejected as set forth below.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-5 are rejected under 35 U.S.C. 103 as being unpatentable over Sekine (U.S. 6,054,484), in view of Juturu (WO2022/040026).
Sekine describes a cataplasm, synonymous with the instant “poultice,” which combines 2% diclofenac, a drug recited in Claim 5, with sodium polyacrylate, a “water soluble polymer” per applicants own specification (see Specification Pg.22), 1% sodium carboxymethyl cellulose addressing Claim 2, 2% light silicic acid which Sekine indicates is a filler equivalent to the presently claimed silicic anhydride (synonymous with silica, see “Millipore Sigma”), addressing Claim 3, and a combination of polybutene and gelatin which Sekine indicates provides adhesive properties to the composition, which is spread on a non-woven fabric backing layer. Col.10-11: “Example I-5”; Col.5, L.10 – Col.6, L.7. By describing a particular embodiment containing 2% sodium carboxymethyl cellulose with 1% silicic acid, which Sekine indicates is a filler equivalent to the presently claimed silicic anhydride, Sekine describes a composition wherein the mass ratio of the carboxymethylcellulose to the silicic anhydride is 1:2, addressing Claim 4.
Sekine does not, however, describe using a silicic anhydride or silica having a D50 within the range of 0.2-9 microns.
Juturu also describes compositions which can be formulated as transdermal or topical drug delivery systems ([0018]), which employ silica as a stabilizer ([0064]), and more particularly silica particles having a D50 size of less than about 8 microns, a value overlapping and therefore rendering obvious the silica particle size range claimed. [0080], See In re Peterson, 315 F.3d 1325, 1329 (Fed. Cir. 2003) (“A prima facie case of obviousness typically exists when the ranges of a claimed composition overlap the ranges disclosed in the prior art.”).
It would have been prima facie obvious to have used such particles as the silica in the cataplasms of Sekine, owing to the fact that Sekine teaches that silica may serve as a filler in the cataplasms described, and Juturu indicates that silica particles having the claimed particle sizes are suitable for use in transdermal drug delivery systems. Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945).
Response to Arguments
Applicant's arguments filed 13 August 2026 have been fully considered but they are not persuasive.
Applicants first assert that the claims as amended now define a composition which provides unexpectedly improved results, specifically concerning the critical effect of silicic anhydride (silicon dioxide or silica) particle size on the adhesiveness, “stickiness” and appearance of adhesive layers containing them. To be sure, the law is replete with cases in which the difference between the claimed invention and the prior art is some range or other variable within the claims; In such a situation, the applicant must show that the particular range is critical, generally by showing that the claimed range achieves unexpected results relative to the prior art range. In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). The evidence relied upon should establish “that the differences in results are in fact unexpected and unobvious and of both statistical and practical significance.” Ex parte Gelles, 22 USPQ2d 1318, 1319 (Bd. Pat. App. & Inter. 1992). Here, applicants data as provided in the disclosure as originally filed fails to meet the standard required to demonstrate the criticality of the silica particles on the adhesiveness of the compositions claimed. The data provided lacks the requisite statistical analysis, or even a complete disclosure of the data relied upon (specifically any indication of the standard deviation from the averages provided) to permit a skilled artisan to conclude the silica particle size is in fact critical to the adhesiveness of the compositions. This renders it impossible for a skilled artisan to ascertain whether the differences shown are in fact significant. This is compounded by the fact that the data which is presented demonstrates absolutely no difference in layer appearance, and indeed provides “evaluation” data which is identical in adhesiveness between comparative example 7 and example 5, and stickiness between example 7 and comparative example 8. While differences in “evaluation” and the “average scores” are provided, absent appropriate analysis, or even complete disclosure of the data relied on to reach these conclusions, the record does not provide evidence of the requisite statistical and practical differences needed to establish the criticality of the silica particle sizes on composition adhesive properties. Furthermore, Applicants are reminded that “[e]xpected beneficial results are evidence of obviousness of a claimed invention, just as unexpected results are evidence of unobviousness thereof.” In re Gershon, 372 F.2d 535, 538, 152 USPQ 602, 604 (CCPA 1967), see also In re Skoner, 517 F.2d 947, 950 (CCPA 1975). The art available at the time the instant application was filed demonstrates that the impact of silica particle size on adhesive properties of adhesive transdermal compositions was in fact well-known. See Zbigniew Czech, et al, Water-Borne Pressure-Sensitive Adhesive Acrylics Modified Using Amorphous Silica Nanoparticles, 18 Pol. J Chem. Tech. 124 (2016); Beili Pang, et al, Improvement of Thermal Stability of UV Curable Pressure Sensitive Adhesive by Surface Modified Silica Nanoparticles, 178 Mat. Sci. Eng. B 1212 (2013); Zheng Lu & Reza Fassihi, Influence of Colloidal Silicon Dioxide on Gel Strength, Robustness, and Adhesive Properties of Diclofenac Gel Formulation for Topical Application, 16 AAPS PharmSciTech 636 (2014); Yating Gao, et al, Multifunctional Role of Silica in Pharmaceutical Formulations, 23 AAPS PharmSciTech 90 (2022). On the basis of the record, it cannot be said applicants have demonstrated that the silica particle size does in fact provide an unexpected result, and applicants arguments on this basis are unpersuasive.
Applicant asserts that the teachings of Juturu are directed towards oral compositions, rather than transdermal applicants, do not describe the alleged improvements applicants have realized, and therefore cannot render obvious the invention claimed. Applicants are reminded that art is art, not only for what it expressly teaches, but also for what it would reasonably suggest to the skilled artisan, including alternative or non-preferred embodiments. Merck & Co. v. Biocraft Laboratories, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989). While Juturu may focus on oral dosage forms, a position the Examiner does not concede, Juturu nevertheless describes the use of such silica particles in transdermal applications, a position applicants themselves concede. See pg. 7 (“”In Juturu, a transdermal delivery system is merely exemplified…”). That broad ranges of silica particles are described does nothing to detract from the fact that those ranges encompass those of the present claims, rendering them obvious. See Peterson, supra.
For at least these reasons, applicants arguments are unpersuasive.
Conclusion
No Claims are allowable.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN M BASQUILL whose telephone number is (571)270-5862. The examiner can normally be reached Monday through Thursday, 5:30 AM to 4 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at (571) 272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SEAN M BASQUILL/Primary Examiner, Art Unit 1614